Thomas Sweeney Heard

Array ( [id] => 18932306 [patent_doc_number] => 11884713 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Acylated glucagon analogues [patent_app_type] => utility [patent_app_number] => 17/369061 [patent_app_country] => US [patent_app_date] => 2021-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12205 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 327 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17369061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398225 [patent_doc_number] => 20220040315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => NUCLEASE-DENDRIMER FORMULATIONS FOR COVID-19 AND BROAD-SPECTRUM ANTIVIRAL THERAPY AND PROPHYLAXIS [patent_app_type] => utility [patent_app_number] => 17/367357 [patent_app_country] => US [patent_app_date] => 2021-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11718 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18964180 [patent_doc_number] => 11897931 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => MANP analogues [patent_app_type] => utility [patent_app_number] => 17/359088 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 16202 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17359088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292216 [patent_doc_number] => 20210388055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => FACTOR VIII PROTEINS HAVING ANCESTRAL SEQUENCES, EXPRESSION VECTORS, AND USES RELATED THERETO [patent_app_type] => utility [patent_app_number] => 17/355656 [patent_app_country] => US [patent_app_date] => 2021-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17355656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19353025 [patent_doc_number] => 12053450 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-06 [patent_title] => FAP-activated therapeutic agents, and uses related thereto [patent_app_type] => utility [patent_app_number] => 17/330848 [patent_app_country] => US [patent_app_date] => 2021-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 28 [patent_no_of_words] => 24001 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17244748 [patent_doc_number] => 20210364491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => Biorecognition Elements for Detection of Fungi and Bacteria in Fuel Systems [patent_app_type] => utility [patent_app_number] => 17/323205 [patent_app_country] => US [patent_app_date] => 2021-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17323205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17050720 [patent_doc_number] => 20210260154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => METHODS FOR ATTENUATING RELEASE OF INFLAMMATORY MEDIATORS AND PEPTIDES USEFUL THEREIN [patent_app_type] => utility [patent_app_number] => 17/307471 [patent_app_country] => US [patent_app_date] => 2021-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17307471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399606 [patent_doc_number] => 20220041696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => POLYPEPTIDE TARGETING APTAMERS FOR CHARACTERIZATION, CAPTURE, AND CLINICAL MANAGEMENT OF CIRCULATING TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 17/222616 [patent_app_country] => US [patent_app_date] => 2021-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17222616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140213 [patent_doc_number] => 20210308224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => TREATMENT FOR SARS-COV-2 AND OTHER CORONAVIRUSES [patent_app_type] => utility [patent_app_number] => 17/221009 [patent_app_country] => US [patent_app_date] => 2021-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11413 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17221009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399586 [patent_doc_number] => 20220041676 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => GIP AGONIST COMPOUNDS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/221287 [patent_app_country] => US [patent_app_date] => 2021-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14465 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17221287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19519807 [patent_doc_number] => 12121505 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Fap-activated therapeutic agents, and uses related thereto [patent_app_type] => utility [patent_app_number] => 17/220635 [patent_app_country] => US [patent_app_date] => 2021-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 28 [patent_no_of_words] => 24260 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17220635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140079 [patent_doc_number] => 20210308090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO [patent_app_type] => utility [patent_app_number] => 17/220675 [patent_app_country] => US [patent_app_date] => 2021-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23998 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17220675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17111788 [patent_doc_number] => 20210292385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => Stabilized BCL9 Peptides for Treatment of Aberrant WNT Signaling [patent_app_type] => utility [patent_app_number] => 17/215698 [patent_app_country] => US [patent_app_date] => 2021-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34727 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17215698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915812 [patent_doc_number] => 20210188904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => METHOD FOR PRODUCING LACOSAMIDE AND INTERMEDIATE THEREOF [patent_app_type] => utility [patent_app_number] => 17/196167 [patent_app_country] => US [patent_app_date] => 2021-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11721 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17196167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17005477 [patent_doc_number] => 20210236638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => COMBINATION THERAPIES FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/188988 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17188988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961845 [patent_doc_number] => 12331333 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Enhancers of neurolysin activity [patent_app_type] => utility [patent_app_number] => 17/186489 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 39 [patent_no_of_words] => 23213 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17186489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16870100 [patent_doc_number] => 20210163567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => Method of Delivering a Centrally-Acting Peptide Derivative, and Method of Treating a Neuropsychiatric Disorder [patent_app_type] => utility [patent_app_number] => 17/172408 [patent_app_country] => US [patent_app_date] => 2021-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868545 [patent_doc_number] => 20210162012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/157363 [patent_app_country] => US [patent_app_date] => 2021-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16781 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17157363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806118 [patent_doc_number] => 20210128671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => ADIPONECTIN PEPTIDOMIMETICS FOR TREATING OCULAR DISORDERS [patent_app_type] => utility [patent_app_number] => 17/146397 [patent_app_country] => US [patent_app_date] => 2021-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19783 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17146397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762362 [patent_doc_number] => 20210107943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => CO-ASSEMBLY PEPTIDES, NANOSTRUCTURES, AND METHODS OF MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/124384 [patent_app_country] => US [patent_app_date] => 2020-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17124384 [rel_patent_id] =>[rel_patent_doc_number] =>)